Virus and radiation combo takes aim at tough sarcomas

NCT ID NCT06660810

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether injecting a modified herpes virus (TVEC) directly into tumors, combined with radiation therapy before surgery, can shrink advanced soft tissue sarcomas. The study enrolled 2 adults with specific sarcoma types that could not be removed with clear margins. The main goal is to see if at least 90% of the tumor dies from the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Talimogene laherparepvec (TVEC), a modified herpes virus that attacks cancer cells
What this could lead to
If it works, this combination could shrink sarcomas enough to allow successful surgery, potentially improving survival and reducing recurrence.
What could go wrong
This is a very early, tiny trial (only 2 participants) with no control group. The virus may cause flu-like symptoms or injection site reactions, and the approach may not work for all sarcoma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Iowa

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.